Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant Trop2 (Sacituzumab Biosimilar) antibody

This Humanized Monoclonal antibody specifically detects Trop2 (Sacituzumab Biosimilar) in FACS and in vivo. It exhibits reactivity toward Human.
Catalog No. ABIN7795133
-15% Promotion 2026
$771.54
$907.69
save $136.15 (-15 %)
Plus shipping costs $50.00
5 mg
Shipping to: United States
Delivery in 6 to 8 Business Days

Quick Overview for Recombinant Trop2 (Sacituzumab Biosimilar) antibody (ABIN7795133)

Target

Trop2 (Sacituzumab Biosimilar)

Antibody Type

Recombinant Antibody

Reactivity

Human

Host

  • 4
  • 1
Humanized

Clonality

  • 4
  • 1
Monoclonal

Conjugate

  • 4
  • 1
This Trop2 (Sacituzumab Biosimilar) antibody is un-conjugated

Application

  • 4
  • 3
  • 1
  • 1
  • 1
  • 1
Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade

Research Grade
  • Expression System

    Mammalian cells

    Purpose

    Sacituzumab Biosimilar, Endotoxin 0.05 EU/mg

    Characteristics

    What is sacituzumab biosimilar research grade? Sacituzumab Biosimilar uses the same protein sequences as the therapeutic antibody sacituzumab. Sacituzumab govitecan is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. Triple-negative breast cancer is a type of breast cancer that tests negative for estrogen receptors, progesterone receptors and human epidermal growth factor receptor 2 (HER2) protein. Therefore, triple-negative breast cancer does not respond to hormonal therapy medicines or medicines that target HER2. Sacituzumab govitecan is a conjugate of the humanized anti-Trop-2 monoclonal antibody linked with SN-38, the active metabolite of irinotecan. Each antibody having on average 7.6 Molecules of SN-38 attached. SN-38 is too toxic to administer directly to patients, but linkage to an antibody allows the drug to specifically target cells containing Trop-2.

    Purification

    Protein A or G affinity column

    Purity

    >95 % by reducing SDS-PAGE

    Endotoxin Level

    Less than 0.5 EU/mg of protein as determined by LAL method

    Immunogen

    Human Trop-2
  • Application Notes

    Optimal working dilution should be determined by the investigator.

    Restrictions

    For Research Use only
  • Format

    Liquid

    Concentration

    > 3 mg/mL

    Storage

    4 °C,-20 °C

    Storage Comment

    Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
  • Target

    Trop2 (Sacituzumab Biosimilar)

    Alternative Name

    Sacituzumab Biosimilar

    Target Type

    Biosimilar
You are here:
Chat with us!